LS Investment Advisors LLC bought a new position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 484 shares of the biotechnology company’s stock, valued at approximately $36,000.
Other institutional investors have also bought and sold shares of the company. Evolution Wealth Advisors LLC purchased a new position in Sarepta Therapeutics during the second quarter worth about $25,000. Trust Co. of Vermont raised its holdings in shares of Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 170 shares in the last quarter. Quad Cities Investment Group LLC raised its holdings in shares of Sarepta Therapeutics by 100.0% during the 3rd quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $32,000. Finally, Nvwm LLC bought a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $45,000. Institutional investors and hedge funds own 94.60% of the company’s stock.
NASDAQ SRPT opened at $96.28 on Friday. Sarepta Therapeutics Inc has a 1-year low of $72.05 and a 1-year high of $158.80. The stock has a 50-day moving average of $84.10 and a 200-day moving average of $113.31. The company has a current ratio of 8.81, a quick ratio of 7.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $6.95 billion, a PE ratio of -17.63 and a beta of 2.19.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.35). Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The firm had revenue of $99.04 million for the quarter, compared to analysts’ expectations of $98.49 million. During the same quarter last year, the company posted ($1.15) EPS. The firm’s revenue was up 26.2% on a year-over-year basis. As a group, equities research analysts forecast that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current fiscal year.
Several brokerages have issued reports on SRPT. William Blair reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research note on Friday, August 9th. Needham & Company LLC decreased their price target on shares of Sarepta Therapeutics from $196.00 to $170.00 and set a “buy” rating on the stock in a research note on Wednesday, August 21st. Royal Bank of Canada set a $204.00 price objective on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 24th. Credit Suisse Group lowered their price objective on shares of Sarepta Therapeutics from $201.00 to $185.00 and set an “outperform” rating for the company in a report on Friday. Finally, Robert W. Baird cut their price objective on shares of Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating for the company in a research note on Tuesday, August 20th. Two analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $187.78.
In related news, Director Richard Barry purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average price of $99.32 per share, for a total transaction of $496,600.00. Following the purchase, the director now directly owns 3,182,065 shares of the company’s stock, valued at approximately $316,042,695.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Douglas S. Ingram purchased 16,252 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average price of $123.07 per share, for a total transaction of $2,000,133.64. Following the purchase, the chief executive officer now directly owns 424,405 shares in the company, valued at $52,231,523.35. The disclosure for this purchase can be found here. Insiders have acquired a total of 35,752 shares of company stock worth $3,940,114 in the last quarter. Company insiders own 6.60% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Story: Cost of Capital
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.